Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (98)	5/11/2001 9:44:25 AM
From: tuck	Read Replies (1) \| Respond to of 598

Tularik makes its ASCO play: >>SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--May 11, 2001-- Tularik Inc. (Nasdaq:TLRK - news) today announced that abstracts containing Phase 1 clinical trial results for its two novel anti-tubulin cancer drugs, T67 and T607, will be presented at the 37th annual meeting of the American Society of Clinical Oncologists (ASCO) in San Francisco on May 11-14. T67 and T607 work by binding to B-tubulin, which is essential for cell division. Anti-tubulin agents are a well established class of cancer therapy compounds. In fact, the most commonly used anti-cancer drug is Taxol® (paclitaxel), an anti-tubulin agent, with annual sales in excess of $1.5 billion. However, one shortcoming of Taxol and other currently used anti-tubulin agents is that they become susceptible to multi-drug resistance. T67 and T607 are distinguished from other tubulin-binding agents in that they bind irreversibly to tubulin and, as a result, have shown efficacy against multi-drug resistant tumors in pre-clinical testing. T67 is also distinguished from other anti-tubulin drugs by its ability to cross the blood-brain barrier, making it potentially useful in the treatment of glioma (brain cancer). Tularik is currently conducting five separate Phase 2 clinical trials for T67 in non-small cell lung cancer, breast cancer, and colorectal cancer, hepatocellular carcinoma (liver cancer) and glioma. In one Phase 1 trial, clinicians have observed a partial response in a patient with liver cancer that was maintained for more than a year. Hepatocellular carcinoma is one of the most common causes of cancer death worldwide and is a particularly aggressive form of cancer with poor patient survival. Abstract numbers 438 and 443 will detail Phase 1 trial data on T67. T607, Tularik's second novel anti-tubulin cancer drug, is a structural analog of T67, and also binds irreversibly to B-tubulin. T607 has a different tissue distribution profile than T67 and does not cross the blood-brain barrier. A partial response in a patient with liver cancer was also observed with T607 suggesting that Tularik's novel anti-tubulin agents may have particular benefit for the treatment of liver cancer. T607 is currently undergoing Phase I dose-escalation studies in the U.S., the U.K. and Canada. Abstract number 442 will detail information on T607 Phase 1 studies.<< snip Cheers, Tuck